1-20 of 536
Farhad Ravandi, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Andrew H. Wei, MBBS, FRACP, FRCPA, PhD, Hartmut Döhner, MD, Christopher Pocock, MBBS, Pau Montesinos, MD PhD, Boris Afanasyev, MD DSci, Hervé Dombret, MD, Farhad Ravandi, MD, Hamid Sayar, MD MSc, Jun Ho Jang, MD PhD, Kimmo Porkka, MD, Dominik Selleslag, MD, Irwindeep Sandhu, MD, Mehmet Turgut, MD, Valentina Giai, MD, Yishai Ofran, MD, Merih Kizil Cakar, MD, Aida Botelho de Sousa, MD, Justyna Rybka, MD PhD, Chiara Frairia, MD, Lorenza Borin, MD, Germana Beltrami, MD, Jaroslav Cermak, MD PhD, Gert J. Ossenkoppele, MD PhD, Ignazia La Torre, MD, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, CL Beach, PharmD, Gail J. Roboz, MD
Journal: Blood
Blood (2019) 134 (Supplement_2): LBA-3.
https://doi.org/10.1182/blood-2019-132405
Published: 2019
Journal Articles

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

Naval G. Daver, MD, Guillermo Garcia-Manero, MD, Marina Y Konopleva, MD PhD, Mansour Alfayez, MDMS, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSc, Jorge E. Cortes, MD, Farhad Ravandi, MD, Hussein Abbas, MD BS, Sreyashi Basu, PhD, Elias Jabbour, MD, Sherry A. Pierce, BSN, BA, Zeev E. Estrov, MD, Koichi Takahashi, MD, Jing Ning, PhD, Steven M. Kornblau, MD, Koji Sasaki, MD, Lucia Masarova, MD, Wilmer Flores, James P Allison, PhD, Padmanee Sharma, MD PhD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 830.
https://doi.org/10.1182/blood-2019-131494
Published: 2019
Journal Articles

Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)

Guillaume Richard-Carpentier, MD, Hagop M. Kantarjian, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Joseph D. Khoury, MD, Farhad Ravandi, MD, Nicholas J. Short, MD, Rita Khouri, Koichi Takahashi, MD, Maro Ohanian, DO, Gautam M. Borthakur, MD, Marina Y Konopleva, MD PhD, Naval G. Daver, MD, Zeev E. Estrov, MD, Yesid Alvarado, MD, Nitin Jain, MD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Michelle Velasquez, RN, Patrice Nasnas, MD, Susan O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1299.
https://doi.org/10.1182/blood-2019-130283
Published: 2019
Journal Articles

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

Geoffrey L. Uy, MD, Ibrahim Aldoss, MD, Matthew C Foster, MD, David A Sallman, MD, Kendra L. Sweet, MD, David A. Rizzieri, MD, Peter H. Sayre, MD PhD, Anjali S. Advani, MD, Ashkan Emadi, MD, Matthew J. Wieduwilt, MD PhD, Norbert Vey, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Tamara Moyo, MD PhD, Sarah E. Church, PhD, Michael P. Rettig, PhD, Martha L. Arellano, MD, John E. Godwin, MD, Bob Löwenberg, MD PhD, Gerwin Huls, MD PhD, Farhad Ravandi, MD, John Muth, MS, Kathy Tran, Mojca Jongen-Lavrencic, MD PhD, Erin Timmeny, Max S. Topp, MD, Stefania Paolini, MD PhD, Kuo Guo, MSc, Teia Curtis, Jian Zhao, PhD, Jayakumar Vadakekolathu, PhD, Jon M. Wigginton, MD, Ezio Bonvini, MD, Sergio Rutella, MDPhDFRCPath, Roland B. Walter, MD PhD MS, Jan K Davidson-Moncada, MD PhD, John F. DiPersio, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 733.
https://doi.org/10.1182/blood-2019-122073
Published: 2019
Journal Articles

Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy

Nicholas J. Short, MD, Hind Rafei, MD, Naval G. Daver, MD, Hyunsoo Hwang, Jing Ning, PhD, Jorge E. Cortes, MD, Jeffrey L. Jorgensen, MD PhD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSc, Sa A Wang, MD, Elias Jabbour, MD, Uday Popat, MD, Betul Oran, MDMS, Marina Y Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Gautam M. Borthakur, MD, Kapil N. Bhalla, MD, Ghayas C. Issa, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 735.
https://doi.org/10.1182/blood-2019-122779
Published: 2019
Journal Articles

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Xuelin Huang, PhD, Nitin Jain, MD, Koji Sasaki, MD, Rita Khouri, Naval G. Daver, MD, Naveen Pemmaraju, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Yesid Alvarado, MD, Marina Y Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Musa E. Yilmaz, MD, Gautam M. Borthakur, MD, Jan A. Burger, MD PhD, Steven M. Kornblau, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSc, Alessandra Ferrajoli, MD, Jovitta Jacob, RN, Meagan Rostykus, RN, Rebecca Garris, MSc, Marygrace Ward, RDC, Binru Huang, RDC, Corabelle Encarnacion, RDC, Christopher Loiselle, BS, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 823.
https://doi.org/10.1182/blood-2019-125136
Published: 2019
Journal Articles

Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens

Abhishek Maiti, MBBS, Caitlin R. Rausch, PharmD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Maro Ohanian, DO, Nicholas J. Short, MD, Yesid Alvarado, MD, Christopher B. Benton, MD, Christopher B. Benton, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Musa E. Yilmaz, MD, Nitin Jain, MD, Steven M. Kornblau, MD, Guillermo Montalban Bravo, MD, Koji Sasaki, MD, Michael Andreeff, MD PhD, Prithviraj Bose, MD, Alessandra Ferrajoli, MD, Ghayas C. Issa, MD, Elias Jabbour, MD, Lucia Masarova, MD, Michael E. Rytting, MD, Philip A. Thompson, MBBS, Sa A Wang, MD, Sergej Konoplev, Zhining Chen, Maitrayee Goswami, Rita Maduike, Julio A Guerrero, RN, Qi Zhang, PhD, Antonio Cavazos, Helen Ma, MS, Carol A. Bivins, RN, Allison Wade, Shadiat L Adewale, Susan Tse, Robin Thomas, Kenneth Vaughan, RN, Sherry A. Pierce, BSN, BA, Jing Ning, PhD, Wei Qiao, PhD, John S. Welch, MD PhD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD, Courtney D. DiNardo, MD MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 738.
https://doi.org/10.1182/blood-2019-128909
Published: 2019
Journal Articles

Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

Partow Kebriaei, MD, Pinaki P Banerjee, PhD, Christina Ganesh, BSN, RN, Mecit Kaplan, MS, Vandana Nandivada, BS, MS, Ana Karen Nunez Cortes, MD, Amin M. Alousi, MD, David Marin, MD, Elizabeth J. Shpall, MD, Rohtesh Mehta, MD, Farhad Ravandi, MD, Elias Jabbour, MD, Hagop M. Kantarjian, MD, Richard E. Champlin, MD, Katayoun Rezvani, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1298.
https://doi.org/10.1182/blood-2019-125931
Published: 2019
Journal Articles

Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis

Lucia Masarova, MD, Srdan Verstovsek, MD PhD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Jorge E. Cortes, MD, Elias Jabbour, MD, Maro Ohanian, DO, Lingsha Zhou, Sherry A. Pierce, BSN, BA, Romany Gergis, Gautam M. Borthakur, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MDMSc, Farhad Ravandi, MD, Marina Y Konopleva, MD PhD, Kiran Naqvi, MDMPH, Koji Sasaki, MD, Zeev E. Estrov, MD, Guillermo Garcia-Manero, MD, Carlos E. Bueso-Ramos, MD PhD, Hagop M. Kantarjian, MD, Naval G. Daver, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1656.
https://doi.org/10.1182/blood-2019-130691
Published: 2019
Journal Articles

Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes

Guillermo Montalban-Bravo, MD, Rashmi Kanagal-Shamanna, MD, Christopher B. Benton, MD, Caleb Class, PhD, Kelly S. Chien, MD, Koji Sasaki, MD, Kiran Naqvi, MDMPH, Yesid Alvarado, MD, Tapan M. Kadia, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Naval G. Daver, MD, Koichi Takahashi, MD, Courtney D. DiNardo, MDMSc, Elias Jabbour, MD, Gautam M. Borthakur, MD, Naveen Pemmaraju, MD, Marina Y Konopleva, MD PhD, Sherry A. Pierce, BSN, BA, Carlos E. Bueso-Ramos, MD PhD, Michael Andreeff, MD PhD, Keyur P. Patel, MBBS, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1711.
https://doi.org/10.1182/blood-2019-124978
Published: 2019
Journal Articles

Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes

Guillermo Montalban-Bravo, MD, Elias Jabbour, MD, Caleb Class, PhD, Nicholas J. Short, MD, Rashmi Kanagal-Shamanna, MD, Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Naveen Pemmaraju, MD, Koji Sasaki, MD, Zeev E. Estrov, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Yesid Alvarado, MD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD MS, David P. Steensma, MD, Amy E. DeZern, MD, Gail J. Roboz, MD, Hui Yang, PhDMD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1715.
https://doi.org/10.1182/blood-2019-129141
Published: 2019
Journal Articles

Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Rashmi Kanagal-Shamanna, MD, Guillermo Montalban-Bravo, MD, Caleb Class, PhD, Koji Sasaki, MD, Christopher B. Benton, MD, Kelly Soltysiak, PhD, Elias Jabbour, MD, Tapan M. Kadia, MD, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Mark Routbort, MD PhD, Irene Ganan-Gomez, PhD, Yue Wei, PhD, Gautam M. Borthakur, MD, Farhad Ravandi, MD, Kim-Anh Do, PhD, L. Jeffrey Medeiros, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1719.
https://doi.org/10.1182/blood-2019-130545
Published: 2019
Journal Articles

Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome

Koji Sasaki, MD, Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Elias Jabbour, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Kiran Naqvi, MDMPH, Naval G. Daver, MD, Sherry A. Pierce, BSN, BA, Koichi Takahashi, MD, Courtney D. DiNardo, MDMSc, Graciela M. Nogueras González, MPH, Keyur Patel, MD PhD, Kelly Soltysiak, PhD, Junya Sato, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1720.
https://doi.org/10.1182/blood-2019-130155
Published: 2019
Journal Articles

Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)

Jorge Cortes, MD, Guillermo Garcia-Manero, MD, Koji Sasaki, MD, Kiran Naqvi, MDMPH, Yesid Alvarado, MD, Tapan M. Kadia, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Naval G. Daver, MD, Koichi Takahashi, MD, Elias Jabbour, MD, Gautam M. Borthakur, MD, Naveen Pemmaraju, MD, Marina Y Konopleva, MD PhD, Sherry A. Pierce, BSN, BA, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Hagop M. Kantarjian, MD, Guillermo Montalban Bravo, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1726.
https://doi.org/10.1182/blood-2019-126005
Published: 2019
Journal Articles

Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML)

Tomoyuki Tanaka, Kiyomi Morita, MD, Feng Wang, PhD, Latasha Little, Curtis Gumbs, Jairo Matthews, Courtney D. DiNardo, MDMSc, Tapan M. Kadia, MD, Farhad Ravandi, MD, Marina Y Konopleva, MD PhD, Hagop M. Kantarjian, MD, Richard E. Champlin, MD, Guillermo Garcia-Manero, MD, P Andrew Futreal, PhD, Koichi Takahashi, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 17.
https://doi.org/10.1182/blood-2019-122274
Published: 2019
Journal Articles

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Maria R Vazquez, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Susan O'Brien, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Guillermo Garcia-Manero, MD, Sara E Dellasala, BS, Kathleen A Kehr, MD, Sherry A. Pierce, BSN, BA, Mary B. Rios, RN, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2927.
https://doi.org/10.1182/blood-2019-132246
Published: 2019
Journal Articles

Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs)

Jorge Cortes, MD, Hagop M. Kantarjian, MD, Guillaume Richard-Carpentier, MD, Gautam M. Borthakur, MD, Farhad Ravandi, MD, Kiran Naqvi, MDMPH, Koji Sasaki, MD, Tapan M. Kadia, MD, Srdan Verstovsek, MD PhD, Guillermo Garcia-Manero, MD, Courtney D. DiNardo, MDMSc, Naveen Pemmaraju, MD, Naval G. Daver, MD, Prithviraj Bose, MD, Sherry A. Pierce, BSN, BA, Samuel Dara, MBBS, Elias Jabbour, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2941.
https://doi.org/10.1182/blood-2019-121784
Published: 2019
Journal Articles

Prognostic Significance of IKZF1 , PAX5 , and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib

Yuya Sasaki, MD PhD, Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Rebecca Garris, MSc, Nitin Jain, MD, Koji Sasaki, MD, Farhad Ravandi, MD, Marina Y Konopleva, MD PhD, Michael E. Rytting, MD, Guillermo Garcia-Manero, MD, Latasha Little, BS, Curtis Gumbs, Li Zhao, PhD, P. Andrew Futreal, PhD, Feng Wang, PhD, Koichi Takahashi, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2753.
https://doi.org/10.1182/blood-2019-122017
Published: 2019
Journal Articles

Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Guillaume Richard-Carpentier, MD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD, Keyur P. Patel, MBBS, PhD, Kathryn G. Roberts, PhD, Zhaohui Gu, PhD, Farhad Ravandi, MD, Nitin Jain, MD, Nicholas J. Short, MD, Guillermo Garcia-Manero, MD, Heather M Schroeder, Monica Kwari, BSN, Rebecca Garris, MSc, Rita Khouri, Mike Jones, RDC, Christopher Loiselle, BS, Jorge E. Cortes, MD, Koji Sasaki, MD, Ghayas C. Issa, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MDMSc, Srdan Verstovsek, MD PhD, Naval G. Daver, MD, Charles G. Mullighan, MBBS, MD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2577.
https://doi.org/10.1182/blood-2019-129884
Published: 2019
Journal Articles

Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Using Duplex Sequencing (DS)

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Rashmi Kanagal-Shamanna, MD, Koji Sasaki, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Marina Y Konopleva, MD PhD, Ghayas C. Issa, MD, Steven M. Kornblau, MD, Guillermo Garcia-Manero, MD, Victor Rivera, PhD, Rebecca Garris, MSc, Jacob Higgins, PhD, Gabriel Pratt, PhD, Lindsey N. Williams, PhD, Charles C. Valentine, MS, Jesse J. Salk, MD PhD, Justin Prichard, PhD, Jerald P. Radich, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2578.
https://doi.org/10.1182/blood-2019-125131
Published: 2019